Entity
  • MindMed

    Created in 2019
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    395 32,121
  • Activities

  • Technologies

  • Entity types

  • Location

    One World Trade Center, 285 Fulton St, New York, NY 10006, USA

    New York

    United States of America

  • Employees

    Scale: 51-200

    Estimated: 91

  • Engaged corporates

    3
    0 2
  • Added in Motherbase

    1 year, 2 months ago
Description
  • Value proposition

    MindMed is a clinical-stage biopharma company developing novel products to treat brain health disorders

    MindMed is a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.

    MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.

  • Rethinking Brain Health | MindMed

    MindMed works to deliver on the therapeutic potential of psychedelics and other novel compounds to address unmet patient needs in the fields of psychiatry, addiction, pain and neurology.

  • https://mindmed.co/
Corporate interactions BETA
Corporate TypeTweets Articles
MSD
MSD
Pharmaceutical, Pharmaceutical Manufacturing
MSD
Pharmaceutical, Pharmaceutical Manufacturing
Other

4 Nov 2019


Bayer
Bayer
Chemistry, Pharmaceutical, Chemical Manufacturing
Bayer
Chemistry, Pharmaceutical, Chemical Manufacturing
Other

12 Sep 2019


Nasdaq
Nasdaq
Finance, Financial Services
Nasdaq
Finance, Financial Services
Other

26 Nov 2023


Similar entities
Loading...
Loading...
Social network dynamics